ISO Plant Derived Recombinant HSA Human Serum Albumin For MMR Vaccine

Plant-derived Recombinant human serum albumin for MMR vaccine

Description

Measles, mumps, and rubella were endemic diseases in many countries worldwide prior to the introduction of vaccines against these diseases. The diseases have a huge impact on the health of children and a serious burden on the family. Currently, MMR vaccine is the best effective way to eradicate measles and reduce the morbidity and mortality associated with mumps and rubella. MMR vaccine is mostly manufactured using human serum albumin (HSA) derived from human blood in cell culture supplemented and final formulation, which means the manufactures may suffer a potential reduced availability of MMR vaccine because of the shortage supply of HSA. Moreover, blood derived HSA may has safety risk of transmitting human-origin pathogens via vaccination.

The recombinant human serum albumin(OsrHSA), derived from patented rice platform, has been confirmed that have same immunogenicity with HSA, so it can provide a more chemical defined, more safety and more stable alternative for MMR vaccine manufacture.

Compared with the blood derived HSA, OsrHSA is structurelly and biochemically equivalent to the blood derived HSA.

Wuhan Healthgen Biotechnology Corp.(Healthgen Biotech), a high-tech enterprise specializing in plant-derived pharmaceutical research and development, has successfully developed a series of pharmaceutical products, plant-derived Recombinant Human Serum Albumin(OsrHSA) as the representative, by its two-core patented technology platform: rice endosperm specific expression platform(Oryz^HiExp) and proteins purification platform(Oryz^Pur).

Healthgen Biotech’s OsrHSA is expressed from rice grain, which can offer a safer, chemical defined, consistent material in MMR vaccine manufacturer. There are such advantages:

1. Eliminate or reduce of the potential risk of transmitting adventitious agents via vaccination.
2. Avoid the serum quality changes from different batches.
3. Stable supply and no dependence on a process from precious blood source.
4. Simplify the downstream bio-processing.
5. Without Surface active agent Tween 80, reduce the incidence of adverse reactions during injection.

In conclusion, using the OsrHSA produced by Healthgen Biotech, MMR vaccine manufacturers will not worry about the shortage of HSA due to insufficient plasma sources, and the immunogenicity and safety of MMR vaccine production and injection.